A series of high-level conferences held in autumn and winter focused on current challenges to implementing an industrial scale bioeconomy in Europe. In November, the European Commission unveiled a new stock-take of progress in its Bioeconomy Strategy, ahead of an official revision planned in 2018. In a manifesto, stakeholders demand a holistic policy framework.
Emil Billbäck appointed CEO of BONESUPPORT
AppointmentsBONESUPPORT (Nasdaq Stockholm: BONEX) announces that the Board of Directors has appointed Emil Billbäck as the new CEO of BONESUPPORT HOLDING AB. Mr. Billbäck has over 20 years management experience from the life science industry and the Board of Directors is of the opinion that he has the ideal profile to implement the Company’s strategy and to deliver shareholder value. He will join BONESUPPPORT on 1st March 2018 when he will replace Richard Davies who has been the Company’s CEO since January 2016.
Protein keeps breast cancer metastases at bay
Latest NewsSpanish researchers have identified a protein that keeps breast cancer stem cell in a dormant state preventing them from forming metastases. A German team found an endothelial receptor protein that prevents dormant micrometastases in the blood to invade tissue.
Seventure Partners joins US$35m round into Zipongo
Latest NewsVenture capital firm Seventure Partners has joined a US$35m Series B Round in Digital Nutrition Platform Zipongo. The US$9m invested into the Californian company comes from Seventures’ €160m Health for Life Capital fund, the premier fund dedicated to the expanding microbiome and nutrition space.
European bioeconomy entering the next level
BackgroundA series of high-level conferences held in autumn and winter focused on current challenges to implementing an industrial scale bioeconomy in Europe. In November, the European Commission unveiled a new stock-take of progress in its Bioeconomy Strategy, ahead of an official revision planned in 2018. In a manifesto, stakeholders demand a holistic policy framework.
Sanofi takes over Bioverativ in US$11.8bn deal
Latest NewsSeven years after the acquisition of Genzyme, French drug major Sanofi has added another orphan drug player to its portfolio. The company agreed with the management of US blood disorder expert Bioverativ to pay US$11.6bn in cash, a 64% premium on the company’s share price.
The 8th European Biotechnology Guide 2018
Sponsored PublicationsThe European Biotechnology Science & Industry Guide 2018 provides a wealth of information on companies, research institutions, tech parks and providers acting in the life sciences and biotech industry.
Tamper-resistant labels
Sponsored PublicationsSerialisation dominates the discussion about how to implement the Falsified Medicines Directive (2011/62/EU). However, to meet the February 2019 deadline, companies must also pay attention to the second required safety feature: the anti-tampering device. The use of tamper-evident labels is widespread. But beware! There are many challenges associated with these popular tamper-evident devices.
Novel blood test detects eight cancers
Latest NewsItalian, US and Australian researchers have used a blood screening test to detect cancer in patients with 8 different cancers whose tumors had not yet spread. Its sensivity is among the best performances yet for a universal cancer blood test.
Government funds TxCell’s CAR-Treg therapy
Latest NewsFrench immunotherapy company TxCell received a €1.2m funding from the French governemt agency Bpifrance to develop its genetically engineered regulatory T cells (Tregs).
Synpromics Appoints Sarah Haecker Meeks as VP of BD
AppointmentsSynpromics Ltd today announced the appointment of Sarah Haecker Meeks, PhD to the position of Vice President, Business Development.